Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2021 07:00 ET | Source: Trevena Inc.

Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences

CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
March 12, 2020 07:01 ET | Source: Trevena Inc.

Trevena Reports Fourth Quarter and Full Year 2019 Results

PDUFA date of August 7, 2020 for IV oliceridine; FDA considers NDA resubmission complete Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734) Announces NIH...
March 05, 2020 17:00 ET | Source: Trevena Inc.

Trevena to Report Fourth Quarter and Full Year 2019 Results on March 12, 2020

CHESTERBROOK, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
February 13, 2020 07:00 ET | Source: Trevena Inc.

Trevena Appoints Scott Applebaum as Chief Legal and Compliance Officer and SVP of Regulatory Affairs

CHESTERBROOK, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
September 27, 2019 07:00 ET | Source: Trevena Inc.

Trevena to Present at the 2019 Cantor Global Healthcare Conference

CHESTERBROOK, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...